From the Cosmetic Dermatology Archives

iPLEDGE and Its Implementation in Dermatology Practices

Author and Disclosure Information

Isotretinoin is one option in a dermatologist’s arma­mentarium for the treatment of acne; however, it is highly teratogenic, and fetal exposure to isotretinoin can cause severe complications. iPLEDGE is a computer-based risk management program designed to help elimi­nate fetal exposure to isotretinoin by mandating how all isotretinoin products are prescribed and dispensed. Optimal success of the iPLEDGE program requires physi­cian prescribers along with their office staff and patients to perform specific responsibilities to ensure that patients do not start isotretinoin therapy while pregnant or become pregnant during treatment. We discuss how to successfully implement the iPLEDGE program in derma­tology practices.


 

Recommended Reading

Triple-combination for severe acne avoids isotretinoin
MDedge Dermatology
Actual acne treatment lasts longer than studies suggest
MDedge Dermatology
Childhood acne: When to worry
MDedge Dermatology
Eat fish and avoid acne?
MDedge Dermatology
Tweeting the truth about acne
MDedge Dermatology
Product News: 05 2013
MDedge Dermatology
Efficacy and Tolerability of Fixed-Combination Acne Treatment in Adolescents
MDedge Dermatology
Cosmetic Corner: Dermatologists Weigh in on OTC Acne Preparations
MDedge Dermatology
Male Acne: The Importance of Gender in Acne Treatment [editorial]
MDedge Dermatology
Safety First: Fractional Nonablative Laser Resurfacing in Fitzpatrick Skin Types IV to VI
MDedge Dermatology